Effectiveness of crizotinib in patients with ROS1-positive non-small-cell lung cancer: real-world evidence in Japan.

Abstract

Aim: Crizotinib, approved in Japan (2017) for ROS1-positive NSCLC, has limited real-world data. Materials & methods: Crizotinib monotherapy real-world effectiveness and treatment status wereanalyzed from claims data (June 2017-March 2021; Japanese Medical Data Vision; 58 patients tested for ROS1-NSCLC). Results: Median duration of treatment ([DoT]; primary end point), any line: 12.9months; 22 patients on crizotinib, 23 discontinued, 13 receiving post-crizotinib treatment. 1L (n=27) median DoT: 13.0months (95% CI, 4.4-32.0months); 13 patients on crizotinib; sevendiscontinued; sevenreceiving post-crizotinib treatment. 2L (n=13) median DoT: 14.0months (95% CI, 4.6-22.2months); 2L+ (n=31): ninepatients on crizotinib; 16 discontinued; sixreceiving post-crizotinib treatment. Post-crizotinib treatments (chemotherapy, cancer immunotherapy, anti-VEGF/R) did not affect crizotinib DoT. Conclusion: Data supplement crizotinib's effectiveness in ROS1-positive NSCLC previously seen in clinical trials/real-world.